公开(公告)号：EP3098602B1

公开(公告)日：2018-10-31

申请号：EP16170158.6

申请日：2016-05-18

申请人： Industry Foundation of Chonnam National University ,  Korea Basic Science Institute

发明人： KIM, Du Woon ,  KWON, Joseph

IPC分类号： A61K38/16 ,  C12Q1/68 ,  G01N33/569 ,  G01N33/50

CPC分类号： G01N33/5088 ,  A61K38/168 ,  C12Q1/68 ,  G01N33/5091 ,  G01N33/56983 ,  G01N2333/08 ,  G01N2333/4603 ,  Y02A50/463

摘要： Discloses are a method for detecting Norovirus using a Norovirus animal model, a method for screening an antivial agent against Norovirus, and a composition for neutralizing the infection with an enteric virus, conaining concanavalin A as an active ingredient, so that the method for detecting Norovirus can allow the distinction between infectious Norovius and non-infectious Norovirus, and the composition can neutralize a virus causing food poisioning.

公开(公告)号：EP2917230B1

公开(公告)日：2018-07-18

申请号：EP13792883.4

申请日：2013-11-12

申请人： Ruprecht-Karls-Universität Heidelberg

发明人： URBAN, Stephan ,  NI, Yi

IPC分类号： C07K14/705 ,  G01N33/50 ,  G01N33/68 ,  A01K67/027

CPC分类号： C07K14/705 ,  A01K67/0278 ,  A01K2267/0337 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10152 ,  C12N2760/10122 ,  C12N2760/10152 ,  C12N2999/005 ,  G01N33/566 ,  G01N2333/02 ,  G01N2333/08 ,  G01N2333/188 ,  G01N2500/02

摘要： The present invention relates to a novel Hepatitis B virus (HBV) and/or Hepatitis D virus (HDV) receptor and its use for the development of cells, cell lines and non-human animals that are susceptible to HBV and/or HDV infection and can be used for immunological studies and/or for the screening of drugs, post-entry restriction factors and host dependency factors. It further relates to the use of the receptor for the identification of compounds useful in the treatment of HBV and/or HDV infection.

公开(公告)号：EP3339862A1

公开(公告)日：2018-06-27

申请号：EP16836983.3

申请日：2016-08-03

申请人： Sekisui Medical Co., Ltd.

发明人： OCHIAI, Yasushi ,  NISHITANI, Kimiyoshi

IPC分类号： G01N33/531 ,  G01N33/543

CPC分类号： G01N33/54393 ,  C07K16/42 ,  G01N33/531 ,  G01N33/543 ,  G01N33/56983 ,  G01N2333/08

摘要： A problem is to provide a method of inhibiting nonspecific reaction unique to feces in a detection method using immunochromatography developing a fecal sample in an insoluble membrane so as to detect an analyte in the sample, and an immunochromatographic test strip used therefor. The present invention provides a method of performing an immunochromatographic reaction in the presence of an anti-IgA antibody so as to detect an analyte in a fecal sample without being affected by nonspecific reaction, and an immunochromatographic test strip used therefor.

公开(公告)号：EP3259357A1

公开(公告)日：2017-12-27

申请号：EP16751843.0

申请日：2016-02-19

申请人： Emergent Biosolutions Canada Inc.

发明人： JOHNSTONE, Darrell

IPC分类号： C12N15/13 ,  A61K39/42 ,  A61P31/12 ,  C07K16/10 ,  C07K16/46 ,  C12N15/63 ,  C12N5/10 ,  C12P21/08 ,  G01N33/569

CPC分类号： C07K16/10 ,  A61K39/42 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/76 ,  C12P21/02 ,  G01N33/56983 ,  G01N2333/08 ,  G01N2469/10

摘要： The present disclosure relates to an antibody or antigen-binding portion thereof that binds to a filovirus. The antibody or antigen-binding portion thereof may have one or more murine CDRs and one or more human framework, regions. Also provided herein are compositions comprising the antibody or antigen-binding portion t hereof, methods of producing the antibody or antigen-binding portion thereof and methods of using the antibody or antigen-binding portion thereof.

公开(公告)号：EP3145540A4

公开(公告)日：2017-12-13

申请号：EP15796952

申请日：2015-05-18

申请人： UNIV CALIFORNIA

发明人： CHENG R HOLLAND ,  XING LI ,  CHEN CHUN CHIEH ,  STARK MARIE CHRISTINE

IPC分类号： A61K39/29 ,  A61K9/50 ,  A61P37/04 ,  C07H21/00 ,  C07K14/08

CPC分类号： C07K14/005 ,  A61K9/5169 ,  A61K2039/5258 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12N2770/28142 ,  C12N2810/40 ,  G01N2333/08

摘要： Modified capsid proteins containing at least a portion of hepatitis E virus (HEV) open reading frame 2 (ORF2) having one or more cysteine residues in a surface variable loop or the C-terminus of HEV ORF2, or a portion thereof, are provided. The modified capsid proteins can be used to form hepatitis E virus (HEV) virus like particles (VLPs) having cysteine functional groups exposed on the outer-surface. The exposed cysteine functional groups can be modified via their thiol reactive group. For example, a bioactive agent, such as a cell-targeting ligand, can be conjugated to the one or more cysteines for targeted delivery of chemically activated nanocapsids.

公开(公告)号：EP3207056A1

公开(公告)日：2017-08-23

申请号：EP15780860.1

申请日：2015-10-14

申请人： Deutsches Krebsforschungszentrum ,  Ruprecht-Karls-Universität Heidelberg

发明人： HANSMAN, Grant ,  KOROMYSLOVA, Anna

IPC分类号： C07K16/10 ,  A61K39/395 ,  G01N33/569

CPC分类号： C07K16/10 ,  C07K7/06 ,  C07K7/08 ,  C07K2317/22 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56983 ,  G01N2333/08

摘要： The present invention relates to a binding polypeptide specifically binding to the amino acid sequence W-V-N-X1-F-Y-X2 (SEQ ID NO: 1), wherein X1 represents any amino acid, preferably Q or P, and wherein X2 represents any amino acid, preferably, T or S in a norovirus polypeptide. The present invention further relates to polynucleotide encoding a binding polypeptide of the present invention an to a host cell comprising the same or the polynucleotide of the invention. The present invention further relates to a method of detecting the presence of a norovirus capsid polypeptide in a sample and to kits, devices, and uses making use of the binding peptide of the invention.

摘要翻译： 本发明涉及特异性结合氨基酸序列WVN-X1-FY-X2（SEQ ID NO：1）的结合多肽，其中X1代表任何氨基酸，优选Q或P，并且其中X2代表任何氨基酸， 优选地，诺如病毒多肽中的T或S. 本发明进一步涉及编码本发明的结合多肽和包含其的宿主细胞或本发明的多核苷酸的多核苷酸。 本发明进一步涉及检测样品中诺如病毒衣壳多肽的存在的方法，以及使用本发明的结合肽的试剂盒，装置和用途。

公开(公告)号：EP2927688A4

公开(公告)日：2016-07-27

申请号：EP13859219

申请日：2013-11-27

申请人： FURUKAWA ELECTRIC CO LTD

发明人： AIZAWA HIDEKI ,  OHKUBO MICHIO ,  MIYOSHI KAZUTOMI

IPC分类号： G01N21/64 ,  B01L3/00 ,  B82Y30/00 ,  G01N21/59 ,  G01N21/84 ,  G01N33/533 ,  G01N33/543 ,  G01N33/552 ,  G01N33/558 ,  G01N33/58

CPC分类号： G01N33/56983 ,  B82Y30/00 ,  G01N21/59 ,  G01N21/6428 ,  G01N21/6489 ,  G01N21/8483 ,  G01N33/558 ,  G01N33/582 ,  G01N2021/6439 ,  G01N2021/8488 ,  G01N2333/08 ,  G01N2333/11 ,  G01N2469/10

公开(公告)号：EP2991657A2

公开(公告)日：2016-03-09

申请号：EP14791918.7

申请日：2014-04-30

申请人： The Chancellor, Masters and Scholars of The University of Oxford ,  Unither Virology, LLC

发明人： LAING, Peter ,  DWEK, Raymond ,  POLLOCK, Stephanie ,  ZITZMANN, Nicole

IPC分类号： A61K31/739 ,  C40B40/14 ,  G01N33/53 ,  G01N33/574 ,  G01N33/576 ,  G01N33/68

CPC分类号： G01N33/92 ,  C12Q1/6883 ,  C12Q1/707 ,  C12Q2600/158 ,  G01N2333/08 ,  G01N2800/26 ,  G01N2800/52

摘要： The present application provides novel lipidomic markers for Hepatitis C and related conditions, such as hepatic fibrosis and hepatocellular carcinoma.

摘要翻译： 丙型肝炎和相关病症的脂质体标记物，治疗肝纤维化和肝细胞癌。 给予该受试者的药剂可以是亚氨基糖苷下的细胞总脂肪酸含量，其可能对丙型肝炎有效。这种亚氨基糖苷可以是例如N-取代的脱氧缺氧神经霉素及其药学上可接受的盐之一，N-取代的脱氧半乳糖吉非霉素 和其药学上可接受的盐和N-取代的Me-脱氧半乳糖吉非霉素及其药学上可接受的盐。 评估丙型肝炎感染或由所述感染引起或与之相关的病症的方法。 该方法包括：从有需要的受试者获得生物样品; 确定所述生物样品中至少一种丙型肝炎脂质体生物标志物的水平; 并将所述水平与所述丙型肝炎脂质体生物标志物的对照水平进行比较，以评估丙型肝炎感染或由所述感染引起的或与受试者相关的病症。

公开(公告)号：EP2909322A2

公开(公告)日：2015-08-26

申请号：EP13847451.5

申请日：2013-10-16

申请人： Monsanto Technology LLC

发明人： HEMMES, Johannes, C. ,  JIA, Lijie

IPC分类号： C12N15/40

CPC分类号： A01N57/16 ,  A01N25/30 ,  A01N63/02 ,  C12N15/1131 ,  C12N15/8283 ,  C12N2310/11 ,  G01N33/56983 ,  G01N2333/01 ,  G01N2333/08 ,  G01N2333/175

摘要： The present invention provides methods for topical treatment and prevention of Tospovirus and/or Geminivirus disease in plants. The invention further provides compositions for treatment of Tospovirus and/or Geminivirus disease in plants, and methods for reducing expression of a Tospovirus and/or Geminivirus gene and for identifying polynucleotides useful in modulating gene expression in plant viruses.

公开(公告)号：EP2797625A4

公开(公告)日：2015-08-12

申请号：EP11878842

申请日：2011-12-30

申请人： UNITED BIOMEDICAL INC

发明人： WANG CHANG YI

IPC分类号： A61K39/12 ,  A61P31/12

CPC分类号： A61K39/12 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/55516 ,  A61K2039/55566 ,  A61K2039/6031 ,  A61K2039/627 ,  A61K2039/70 ,  C12N7/00 ,  C12N2770/10034 ,  G01N33/56983 ,  G01N2333/08

摘要： A peptide-based marker vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS) and a set of immunodiagnostic tests for the prevention, monitoring and control of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) are disclosed. Vaccine formulations according to various embodiments of the invention contain a mixture of peptides derived from PRRSV GP2, GP3, GP4, or GP5 proteins; each peptide individually contains a B cell PRRSV neutralizing/receptor binding epitope which is individually linked to an artificial T helper epitope for enhancement of the respective peptide's immunogenicity; and which can be supplemented with a mixture of peptides representing the T helper epitopes derived from the PRRSV GP4, GP5, M and Nucleocapsid proteins to provide cell mediated immunity. Such viral peptide compositions are prepared in an acceptable delivery system as vaccine formulations and can provide cross protection of PRRSV antibody free pigs from infection upon PRRSV challenge.

摘要翻译： 公开了一种针对猪生殖和呼吸综合征（PRRS）的基于肽的标记疫苗和一套用于预防，监测和控制猪繁殖与呼吸综合征病毒（PRRSV）的免疫诊断试验。 根据本发明各种实施方案的疫苗制剂含有衍生自PRRSV GP2，GP3，GP4或GP5蛋白质的肽的混合物; 每个肽单独含有B细胞PRRSV中和/受体结合表位，其与人工T辅助表位单独连接以增强各自的免疫原性; 并且其可以补充表示衍生自PRRSV GP4，GP5，M和Nucleocapsid蛋白的T辅助表位的肽的混合物，以提供细胞介导的免疫。 这样的病毒肽组合物在可接受的递送系统中制备为疫苗制剂，并且可以在PRRSV攻击时提供免于PRRSV抗体的猪免受感染的交叉保护。